miRNA signature associated with outcome of gastric cancer patients following chemotherapy

Identification of patients who likely will or will not benefit from cytotoxic chemotherapy through the use of biomarkers could greatly improve clinical management by better defining appropriate treatment options for patients. microRNAs may be potentially useful biomarkers that help guide individuali...

Full description

Saved in:
Bibliographic Details
Published in:BMC medical genomics 2011-11, Vol.4 (1), p.79-79, Article 79
Main Authors: Kim, Chang Hee, Kim, Hark K, Rettig, R Luke, Kim, Joseph, Lee, Eunbyul T, Aprelikova, Olga, Choi, Il J, Munroe, David J, Green, Jeffrey E
Format: Article
Language:English
Subjects:
Adult
Biomarkers
Cancer
Cancer therapies
Cell cycle
Cisplatin - pharmacology
Cisplatin - therapeutic use
Discriminant analysis
Disease Progression
Drug dosages
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Female
Fluorouracil - pharmacology
Fluorouracil - therapeutic use
Gene Expression Profiling
Gene Expression Regulation, Neoplastic - drug effects
Humans
Kaplan-Meier Estimate
Male
Medical research
MicroRNAs - genetics
MicroRNAs - metabolism
Middle Aged
Polymerase chain reaction
Prognosis
Real-Time Polymerase Chain Reaction
Reproducibility of Results
Signatures
Stomach - drug effects
Stomach - metabolism
Stomach - pathology
Stomach Neoplasms - drug therapy
Stomach Neoplasms - genetics
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identification of patients who likely will or will not benefit from cytotoxic chemotherapy through the use of biomarkers could greatly improve clinical management by better defining appropriate treatment options for patients. microRNAs may be potentially useful biomarkers that help guide individualized therapy for cancer because microRNA expression is dysregulated in cancer. In order to identify miRNA signatures for gastric cancer and for predicting clinical resistance to cisplatin/fluorouracil (CF) chemotherapy, a comprehensive miRNA microarray analysis was performed using endoscopic biopsy samples. Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P
ISSN:1755-8794
1755-8794
DOI:10.1186/1755-8794-4-79